AKT1 and breast cancer: The combination of a dual AKT and p70 ribosomal protein S6 kinase (p70S6K) inhibitor (LY2780301) with paclitaxel (taxane) in advanced BC was studied in patients with driver mutations of PI3KCA, AKT1, and TP53 in their tumors.